Biosimilar use in the United States: An analysis of filgrastim and infliximab

被引：0
|
作者：
Dutcher, Sarah K. [1 ]
Eworuke, Efe [1 ]
Fazio-Eynullayeva, Elnara [2 ,3 ]
Dee, Elizabeth [2 ,3 ]
Nguyen, Michael D. [1 ]
Panozzo, Catherine A. [2 ,3 ]
机构：
[1] US FDA, Silver Spring, MD USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Harvard Pilgrim Hlth Care Inst, Boston, MA USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2019年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
978
引用
收藏
页码：475 / 475
页数：1
相关论文
共 50 条
  • [41] The Emerging Role of Biosimilar Epoetins in Nephrology in the United States
    Fishbane, Steven
    Shah, Hitesh H.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2015, 65 (04) : 537 - 542
  • [42] BRIGHT FUTURE FOR THE USE OF BIOSIMILAR INFLIXIMAB: EVIDENCE-BASED ANALYSIS USING HEALTHCARE CLAIM DATABASE
    Cho, J.
    An, D.
    Jang, S.
    Lee, E.
    VALUE IN HEALTH, 2018, 21 : S300 - S300
  • [43] COST SAVINGS AND THE OPPORTUNITY FOR EXPANDED TREATMENT ACCESS WITH INCREASED USE OF BIOSIMILAR ADALIMUMAB IN THE UNITED STATES
    Shastri, K.
    Clarke, K.
    Ainslie-Garcia, M.
    Ferko, N.
    VALUE IN HEALTH, 2024, 27 (06) : S126 - S126
  • [44] BUDGET IMPACT ANALYSIS OF INTRODUCTION OF RITUXIMAB BIOSIMILAR IN THE UNITED STATES FROM A PAYER PERSPECTIVE
    Ektare, V
    Liu, R.
    Stephens, J.
    Al Taie, A.
    Shelbaya, A.
    VALUE IN HEALTH, 2020, 23 : S16 - S17
  • [45] Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective
    Chaplin, Stephen
    van Stiphout, Joris
    Chen, Anna
    Li, Edward
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2024, 30 (11): : 1226 - 1238
  • [46] BUDGET IMPACT ANALYSIS OF INTRODUCTION OF BEVACIZUMAB BIOSIMILAR IN THE UNITED STATES FROM A PAYER PERSPECTIVE
    Ektare, V
    Liu, R.
    Stephens, J.
    Shelbaya, A.
    Yang, J.
    VALUE IN HEALTH, 2020, 23 : S15 - S15
  • [47] UPTAKE OF FILGRASTIM 'BIOSIMILARS' IN THE UNITED STATES: ANALYSIS OF A MEDICAL TRANSCRIPTION DATABASE OF PATIENT OFFICE VISITS
    Smoyer, K. E.
    Jones, C. A.
    Lane, P. B.
    VALUE IN HEALTH, 2015, 18 (07) : A491 - A491
  • [48] A dissimilar biosimilar? Lichenoid drug eruption induced by an infliximab biosimilar
    Gonzalez, N.
    Patel, P.
    Han, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (04) : 965 - 968
  • [49] Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies
    Harbeck, Nadia
    Gascon, Pere
    Krendyukov, Andriy
    Hoebel, Nadja
    Gattu, Sreekanth
    Blackwell, Kimberly
    ONCOLOGIST, 2018, 23 (04): : 403 - 409
  • [50] Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
    Kerry Mansell
    Hishaam Bhimji
    Dean Eurich
    Holly Mansell
    BMC Health Services Research, 19
12345